Holen Sie sich die Stockscreener-App
24.68
3.78%
0.90
Handel nachbörslich:
24.68
Schlusskurs vom Vortag:
$23.78
Offen:
$23.85
24-Stunden-Volumen:
1.93M
Relative Volume:
0.76
Marktkapitalisierung:
$3.12B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-12.16
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
+16.14%
1M Leistung:
+29.89%
6M Leistung:
+26.05%
1J Leistung:
-28.75%
1-Tages-Spanne:
$23.69
$24.71
1-Wochen-Bereich:
$21.16
$24.70
52-Wochen-Spanne:
$16.10
$35.70
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
24.68 | 3.01B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.67 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.41 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.05 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Yahoo Finance
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What downside risks could hit Apellis Pharmaceuticals Inc. (1JK) stockRecession Risk & AI Optimized Trade Strategies - Newser
Why millennials buy Apellis Pharmaceuticals Inc. (1JK) stockPrice Action & High Accuracy Trade Alerts - Newser
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. (1JK) stock issue positive guidanceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock gets analyst attentionRate Cut & High Conviction Buy Zone Picks - Newser
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases - Investing.com Nigeria
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli - marketscreener.com
Apellis (APLS) Gains Boost from Positive Phase 3 Study Results - GuruFocus
Apellis Pharmaceuticals Announces Positive Phase 3 VALIANT Study Results for EMPAVELI in Treating C3 Glomerulopathy and Primary IC-MPGN - Quiver Quantitative
Transcript : Apellis Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02 - marketscreener.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Performance Summary & AI Powered Market Entry Ideas - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock could be top winnerJuly 2025 Summary & High Yield Equity Trading Tips - Newser
38,572 Shares in Apellis Pharmaceuticals, Inc. $APLS Purchased by Wealthedge Investment Advisors LLC - MarketBeat
Will Apellis Pharmaceuticals Inc. stock deliver long term returnsAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight - GlobeNewswire Inc.
Virtus Investment Advisers LLC Acquires 12,106 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Steward Partners Investment Advisory LLC Buys 18,800 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Geode Capital Management LLC Raises Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Breakout Watch: How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peers2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Apellis Pharmaceuticals, Inc. $APLS Position Increased by Rhenman & Partners Asset Management AB - MarketBeat
Apellis Pharmaceuticals (APLS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trading the Move, Not the Narrative: (APLS) Edition - news.stocktradersdaily.com
Can Sanmitra Commercial Limited Maintain Its Strong Profit MarginsInterest Rate Changes & High Yield Investment Portfolio - earlytimes.in
Apellis Pharmaceuticals, Inc. $APLS Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals (Nasdaq: APLS) to Webcast Investor Chats at 2025 Conferences - Stock Titan
Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch - MSN
9 Oversold Biotech Stocks to Invest In - Insider Monkey
FY2025 Earnings Estimate for APLS Issued By Zacks Research - MarketBeat
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns - Markets Mojo
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsShare Buyback & Safe Swing Trade Setups - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Using AI based signals to follow Apellis Pharmaceuticals Inc.Gold Moves & Free Safe Entry Trade Signal Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):